Absolute Neutrophil Count (ANC) Calculator — Chemotherapy & Infection Risk
The Absolute Neutrophil Count (ANC) is a critical laboratory value used to quantify the number of neutrophils available for fighting infection. It is essential for assessing neutropenia severity, guiding chemotherapy dosing, determining febrile neutropenia risk, and deciding on growth factor support (G-CSF) therapy.
About
Absolute Neutrophil Count (ANC) represents the total number of neutrophil granulocytes in the blood, calculated from the total white blood cell count and the percentage of neutrophils (segmented + bands). It is a cornerstone of infectious risk assessment in oncology, particularly for patients receiving myelosuppressive chemotherapy. ANC < 500 (severe neutropenia) carries the highest risk of febrile neutropenia — a medical emergency requiring prompt evaluation and empiric antibiotics. The ANC is also used to determine eligibility for growth factor prophylaxis (G-CSF) and to guide chemotherapy dose reductions. In non-oncology settings, ANC helps evaluate myelodysplasia, drug-induced agranulocytosis, and other bone marrow disorders.
Formula
ANC = WBC (×10^9/L) × (Neutrophil % + Band %) × 10
The ANC is calculated by multiplying the total white blood cell count (in ×10^9/L) by the sum of segmented neutrophils and band forms (as percentages). The result represents the absolute number of neutrophils per liter of blood. A normal ANC is ≥1.5 ×10^9/L. Values between 1.0-1.5 indicate mild neutropenia, 0.5-1.0 moderate neutropenia, and <0.5 severe neutropenia, which carries significant infection risk.
Score Interpretation
ANC is one of the most important laboratory values in oncology and hematology. It determines the risk of febrile neutropenia, guides prophylactic G-CSF use, and influences chemotherapy dose intensity. The Common Terminology Criteria for Adverse Events (CTCAE) uses ANC to grade neutropenia severity. In clinical practice, ANC trends are more informative than single values, and the nadir ANC (lowest point) after chemotherapy is the key determinant of subsequent cycle dosing.
Normal — 1.5+
ANC ≥1.5 ×10^9/L. No neutropenia. Normal host defense.
Management: No intervention needed based on ANC alone.
Mild Neutropenia — 1–1.499
ANC 1.0-1.5 ×10^9/L. Mild neutropenia. Slightly increased infection risk.
Management: Monitor for infection. Consider repeating CBC.
Moderate Neutropenia — 0.5–0.999
ANC 0.5-1.0 ×10^9/L. Moderate neutropenia. Increased infection risk.
Management: Monitor closely. Consider dose adjustment of myelosuppressive therapy.
Severe Neutropenia — 0–0.499
ANC <0.5 ×10^9/L. Severe neutropenia. Significantly increased risk of febrile neutropenia.
Management: Urgent evaluation for fever. Consider G-CSF. Neutropenic precautions. Empiric antibiotics if febrile.
Reference Ranges
| Population | Normal Range | Notes |
|---|---|---|
| Healthy adults | 1.5 - 8.0 ×10^9/L | Normal range may vary by age, race, and laboratory reference standards |
| African descent (benign ethnic neutropenia) | 1.0 - 6.0 ×10^9/L | Lower baseline ANC is normal in individuals of African descent; does not indicate increased infection risk |
Dr. Khaled Hassan
Dr. Khaled is a cardiology consultant with experience in acute cardiac care.
View medical review board & editorial policy →Example Calculation
A 56-year-old woman receiving chemotherapy for breast cancer presents with fatigue. Labs: WBC 1.8 ×10^9/L, neutrophils 30%, bands 5%. ANC = 1.8 × (30 + 5) / 100 = 0.63 ×10^9/L. This is moderate neutropenia. She is afebrile, so outpatient monitoring is appropriate with G-CSF prophylaxis for subsequent cycles.
Related Conditions
Related Medications
Common Mistakes
Forgetting to include band forms in the calculation
Band forms are immature neutrophils and should be included as they contribute to the available neutrophil pool. Many automated differentials do not separately report bands; in such cases, use total neutrophil percentage only.
Confusing ANC with total WBC for infection risk assessment
A normal WBC does not guarantee a normal ANC. Always calculate ANC explicitly when assessing infection risk, especially in chemotherapy patients, as the WBC may be normal while the neutrophil count is critically low.
Frequently Asked Questions
What ANC threshold defines febrile neutropenia?
When is prophylactic G-CSF indicated?
References
- Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33(28):3199-3212. PubMed
- Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100(2):228-237. PubMed